CSBR News Alert Champions Biotechnlg (CSBR) 0.7000 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Champions Biotechnlg (CSBR) 0.7000 $CSBR

Champions Oncology posts higher loss from operations for Q1 2014
M2 - Fri Sep 12, 7:17AM CDT
Oncology drug company Champions Oncology (Other OTC:CSBR) Thursday reported its loss from operations of USD3.7m for the first quarter of 2015.

Champions Oncology Reports Results for the First Quarter Ended July 31, 2014
PR Newswire - Thu Sep 11, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2014.

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 11
PR Newswire - Tue Sep 09, 9:43AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2014, on Thursday, September 11, 2014, after market close.

Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2014
PR Newswire - Thu Jul 24, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014.

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 24
PR Newswire - Mon Jul 21, 4:28PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2014, on Thursday, July 24, 2014, after market close.

Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer
PR Newswire - Tue Jun 17, 7:00AM CDT
Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients' tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.

Champions Oncology Reports Results for the Third Quarter Ended January 31, 2014
PR Newswire - Thu Mar 13, 3:28PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fiscal third quarter ended January 31, 2014.

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 13
PR Newswire - Mon Mar 10, 9:45AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2014 on Thursday, March 13, 2014, after market close.

Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.

Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.

FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.

Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.

Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.

UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.

Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.

Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions" , a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.

Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA" certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor.

Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.

Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.

OtcbbJournal.com Initiates Coverage on ETAH, CSBR, AIVN and MTPR
Marketwire - Tue Sep 03, 7:01AM CDT
Eternity Healthcare, Inc. (OTCQB: ETAH) is a biopharmaceutical company with technologies in drug delivery, specialty pharmaceuticals and medical devices, currently focusing on the development of new subcutaneous formulation of otherwise intramuscular injectable drugs and needle-free injection systems. If you don't like needles, you need to see this report: http://bit.ly/ETAHREPORT




Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring CRH Stock Performance Over Five Years and Beyond

Updated Category News Views 152

Understanding CRH's Impressive Growth CRH has displayed a remarkable performance in the stock market over the last five years, outshining many of its competitors with a 10.67% annualized return. This impressive growth translates to an average annual return of 23.49% for investors. Currently, CRH boasts a market capitalization of approximately $73.09 billion, making it a...

Continue Reading
Coordinated Care's Health Tour Expands Access Across WA

Updated Category News Views 78

A Grassroots Push for Health Equity Coordinated Care, a subsidiary of Centene Corporation, is hitting the road in Washington state. This isn't about just another healthcare campaign—you’ve got two vans, 'SeeMore' and 'Flossy', bringing essential vision and dental screenings right up to the folks who need them most. Taking Healthcare Directly to Communities Let's be...

Continue Reading
Italy's Antitrust Agency Investigates Snam-Edison Deal

Updated Category News Views 229

Investigation into the Snam and Edison Gas Storage Deal Italy's antitrust agency has recently initiated an investigation concerning the transaction between Snam and Edison involving Edison's gas storage unit. This move reflects the agency's commitment to maintaining healthy competition within the energy sector. Concerns Over Market Competition The Antitrust Authority,...

Continue Reading
Truist Financial Corporation's Quarterly Performance Insights

Updated Category News Views 240

Truist Financial's Results and Earnings Overview Truist Financial Corporation (TFC) announced its latest quarterly results, showcasing a robust financial performance that illustrates the company’s strategic focus on growth and stability. This release reflects the commitment of Truist to enhance the lives of its clients and communities by providing comprehensive...

Continue Reading
Investigation Into Possible Securities Fraud at UnitedHealth Group

Updated Category News Views 350

UnitedHealth Group Under Scrutiny for Securities Claims Ademi & Fruchter LLP has launched an investigation into potential securities fraud claims against UnitedHealth Group Incorporated (NYSE: UNH). This inquiry arises following inaccurate statements made by the company regarding its operational performance and future outlook. Investors and analysts alike express serious...

Continue Reading